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WHAT RIEGEL PORTENDS FOR FDA PREEMPTION 
OF STATE LAW PRODUCTS LIABILITY CLAIMS 
Catherine M. Sharkey* 
INTRODUCTION: PREEMPTION CASES IN SEARCH OF A FRAMEWORK 
In Riegel v. Medtronic, Inc., the U.S. Supreme Court held that a federal 
statute governing regulation of medical devices expressly preempts, or dis-
places, state tort law claims when a device has received FDA premarket ap-
proval.1  A month after the Court issued this opinion, Justice Scalia 
inveighed against the news media coverage of Riegel (an opinion that he au-
thored) at a meeting convened by the Food and Drug Law Institute: 
Scalia said news organizations often fail to focus on the text of the laws the 
Court interprets. . . . The media often make it appear as though the court is 
reaching policy judgments on its own rather than basing its decisions on the 
text of the law at issue in a case. . . .  In some instances, said Scalia, the news 
media leave the impression that no ruling based on the text of a law ―is even 
possible.‖2 
Scalia‘s majority opinion can indeed be fairly characterized as a ―nar-
row, textual interpretation‖ of the preemption clause of the congressionally 
enacted Medical Devices Amendments of 1976 (MDA) to the Federal Food 
Drug and Cosmetics Act (FDCA).3  Express preemption cases, at least in 
theory, can begin and end with statutory text. 
But it is rare to find a products liability preemption case where, in Jus-
tice Scalia‘s words, ―the statute itself speaks clearly to the point at issue.‖4  





  Professor of Law, New York University School of Law.  Kristen Richer provided helpful research 
assistance. 
1
  Riegel v. Medtronic, Inc., 128 S. Ct. 999 (2008) (link). 
2
  Scalia Criticizes News Media, Associated Press, Mar. 27, 2008, available at 
http://www.breitbart.com/article.php?id=D8VM047O4&show_article=1 (link). 
3
  Robert Barnes, Supreme Court Shields Medical-Device Makers, WASH. POST, Feb. 21, 2008, at 
D1, available at http://www.washingtonpost.com/wp-
dyn/content/article/2008/02/20/AR2008022001140.html (quoting Catherine Sharkey, Professor of Law, 
New York University School of Law) (link).  The MDA expressly preempts state requirements that are 
―different from, or in addition to‖ certain federal requirements.  21 U.S.C. § 360k(a) (2008) (link). 
4
  Riegel, 128 S. Ct. at 1009.  Indeed, even with respect to the MDA, the Court interpreted the very 
same preemption clause in Medtronic, Inc. v. Lohr, where it found substantial ―ambiguity in the statute.‖  
518 U.S. 470, 496 (1996) (citation omitted) (link).  See infra note 21 and accompanying text. 
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statutory language is in fact clear.  Often congressional legislation touches 
on some aspects of federal regulation of consumer products, motor vehicles, 
or recreational boats (to name a few examples), without clearly specifying 
the interrelationship with state common law tort claims.  In such legislation, 
Congress often creates confusion by including both a preemption clause, 
which mandates displacement of competing or conflicting state law stan-
dards, and a savings clause, which purports not to upend existing state 
common law liability.5 
Where the language of the preemption and savings clauses points in 
opposite directions, or where Congress has been cryptic or silent on the 
matter, Justice Scalia‘s ode to text will ring hollow.  Courts will have to de-
cide on the basis of implied conflict preemption (as opposed to express 
preemption), looking at the entire statutory and regulatory framework to de-
termine whether state laws either ―make it ‗impossible‘ for private parties to 
comply with both state and federal law,‖6 or, more broadly, whether state 
laws frustrate or ―stand[] as an obstacle to the accomplishment and execu-
tion of the full purposes and objectives of Congress.‖7  Justice Ginsburg‘s 
lone dissent in Riegel may well portend the true battleground in implied 
conflict preemption challenges to come: ―In the absence of legislative preci-
sion . . . courts may face the task of determining the substance and scope of 
Congress‘ displacement of state law.‖8  Where statutory text is indetermi-
nate, where are courts to look? 
Several options present themselves.  First, courts may resort to the 
―presumption against preemption‖ statutory canon to raise the bar against 
interpretations favoring preemption absent clear language by Congress.9  
While this approach retains some appeal for judges and academic commen-





  See National Traffic and Motor Vehicle Safety Act of 1966, 15 U.S.C. § 1392(d) (1988) (current 
version at 49 U.S.C. § 30103(b) (2000) (link)) (preemption clause); id. § 1397(k) (current version at 49 
U.S.C. § 30103(e) (2000) (link)) (savings clause); Consumer Product Safety Act, 15 U.S.C. § 2075(a) 
(2000) (preemption clause) (link); id. § 2074(a) (savings clause) (link); Federal Boat Safety Act of 1971, 
46 U.S.C. § 4306 (2000) (preemption clause) (link); id. § 4311(g) (savings clause) (link). 
6
  Geier v. American Honda Motor Co., 529 U.S. 861, 873 (2000) (link). 
7
  Hines v. Davidowitz, 312 U.S. 52, 67 (1941) (link). 
8
  Riegel, 128 S. Ct. at 1014 (Ginsburg, J., dissenting); see also Lohr, 518 U.S. at 505 (Breyer, J., 
concurring) (―Congress must have intended that courts look elsewhere for help as to just which federal 
requirements pre-empt just which state requirements, as well as just how they might do so.‖). 
9
  The presumption harkens back to mid-twentieth century, when the Court asserted that ―the historic 
police powers of the States [a]re not to be superseded . . . unless that was the clear and manifest purpose 
of Congress.‖  Riegel, 128 S. Ct. at 1013 (Ginsburg, J., dissenting) (alterations in original) (quoting Rice 
v. Sante Fe Elevator Corp., 331 U.S. 218, 230 (1947)). 
10
  See, e.g., Brief of Amicus Curiae Constitutional and Administrative Law Scholars in Support of 
Respondents at 3–4, Philip Morris USA Inc. & Altria Group, Inc. v. Good, No. 07-562 (U.S. June 18, 
2008), 2008 WL 2489869, at *3–4 (―[S]tatutory rules like this Court‘s ‗presumption against preemption‘ 
are the most critical component of this Court‘s federalism doctrine. . . . [and] suggest a lens through 
which this Court should view preemption disputes.‖) (citation omitted). 
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tices.  In fact, this canon was not even mentioned by the majority in 
gel.11 
Second, perhaps—consistent with the media suggestion about Riegel—
the Justices simply vote their policy preferences in these matters.12  If so, 
then we would expect even more room for judicial policymaking in implied 
preemption cases, where Congress has not restricted courts‘ interpretive 
sphere with constraining statutory language.  In one sense, preemption deci-
sions always entail policy choices. After all, the decision that a federal stan-
dard ousts a competing state standard entails a choice that regulation should 
take place exclusively at the federal level, and a concomitant embrace of the 
view that state tort law is a regulatory competitor.  Riegel subscribes to this 
ascendant law-and-economics inspired view of the regulatory role of tort 
law;13 the opposing ―tort as compensation‖ view is nowhere engaged.14 
Justice Scalia‘s majority opinion goes even further down this road, 
casting aspersions on the jury‘s competence to engage in cost-benefit analy-





  Nor can its absence be explained by the fact that Riegel is an express preemption case, for so was 
Lohr, and there, the Court trotted out the trusted presumption as the opening salvo of its preemption 
analysis.  Lohr, 518 U.S. at 485 (―[B]ecause the States are independent sovereigns in our federal system, 
we have long presumed that Congress does not cavalierly pre-empt state-law causes of action.‖).  In fact, 
to date, the Court has—paradoxically—applied the presumption in the express preemption products lia-
bility cases, but not in the implied ones.  See Catherine M. Sharkey, Products Liability Preemption: An 
Institutional Approach, 76 GEO. WASH. L. REV. 449, 458 (2008) [hereinafter Sharkey, Products Liabili-
ty Preemption] (noting that the Court invoked the presumption in Bates v. Dow Agrosciences LLC, 544 
U.S. 431 (2005), Lohr, and Cipollone v. Liggett Group, Inc., 505 U.S. 504 (1992)—all decided on ex-
press preemption grounds—but not in Sprietsma v. Mercury Marine, 537 U.S. 51 (2002), or Geier—the 
seminal implied preemption cases) (link). 
12
  The standard attitudinal model used by political scientists posits that Justices vote their policy 
preferences.  See JEFFREY A. SEGAL & HAROLD J. SPAETH, THE SUPREME COURT AND THE 
ATTITUDINAL MODEL REVISITED 86 (2002); see also SAUL BRENNER & HAROLD SPAETH, STARE 
INDECISIS: THE ALTERATION OF PRECEDENT ON THE SUPREME COURT, 1946–1992, at 109 (1995). 
13
  Riegel, 128 S. Ct. at 1008 (―[W]hile the common-law remedy is limited to damages, a liability 
award ‗can be, indeed is designed to be, a potent method of governing conduct and controlling policy.‘‖) 
(citing Cipollone, 505 U.S. at 521). 
14
  Justice Stevens, champion of the remedial function of tort law in Lohr, see 518 U.S. at 487–89, 
though conceding that ―the overriding purpose of the [FDCA] was to provide additional protection to 
consumers,‖ says nothing further about the disappearance of the tort-as-compensation model in Riegel. 
See 128 S. Ct. at 1011–13 (Stevens, J., concurring in part and concurring in the judgment). Nor does Jus-
tice Kennedy, who dissented in Cipollone, in part on the ground that on the ground that ―tort law has an 
entirely separate function—compensating victims—that sets it apart from direct forms of regulation,‖ 
505 U.S. at 537, express any hesitation on that front in joining the Riegel majority. 
15
  Riegel, 128 S.Ct at 1008 (―A jury, on the other hand, sees only the cost of a more dangerous de-
sign, and is not concerned with its benefits; the patients who reaped those benefits are not represented in 
court.‖).  See also Transcript of Oral Argument at 19, Riegel, 128 S. Ct. 999 (No. 06-179) [hereinafter 
Riegel Oral Argument], available at 
http://www.supremecourtus.gov/oral_arguments/argument_transcripts/06-179.pdf (Scalia, J.) (―What‘s 
going on is simply one jury has decided that in its judgment, there was a safer device that should have 
been used; and because of the judgment of that one jury, the manufacturer is placed at risk in selling a 
device that scientists at the FDA have said is okay. I find that extraordinary.‖) (link). 
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an opinion whose outcome is ostensibly determined exclusively by statutory 
text, Justice Scalia, ―speculat[ing] upon congressional motives,‖ finds a 
―suggest[ion] that the solicitude for those injured by FDA-approved devices 
. . . was overcome in Congress‘s estimation by solicitude for those who 
would suffer without new medical devices if juries were allowed to apply 
the tort law of 50 states to all innovations.‖16 
When such policy predilections undergird preemption decisions—
even, as in Riegel, in the narrowest realm of express preemption based upon 
clear statutory text, let alone in the comparatively unbounded realm of 
implied preemption—it is time to consider alternative models to that of 
courts‘ being left to their own devices under the guise of imputing 
congressional motives. 
This Essay presents that alternative, building upon my previously 
articulated ―agency reference model,‖ which provides a framework for 
courts to decide implied conflict preemption cases by seeking guidance 
from the relevant federal regulatory agency.17  The basic question at the 
core of implied conflict preemption inquiries is whether or not state com-
mon law actions are irreconcilable with, or would stand as an obstacle to, or 
frustrate, the command of federal regulatory directives and goals.  To an-
swer this question, courts need a fine-grained account of the precise regula-
tory review conducted by the agency and evidence as to its compatibility 
with state law tort claims.  The agency reference model aims, as a general 
matter, to facilitate input from federal agencies on these issues. 
As the Court moves beyond Riegel and the realm of express 
preemption to tackle implied conflict preemption in the pharmaceutical 
context in the upcoming Wyeth v. Levine case,18 the time is ripe to consider 
such a model.  Indeed, where, by definition, statutory text alone will not re-
solutely decide the implied conflicts in products liability cases, articulation 
of an analytic framework for where the courts should turn is a pragmatic 
necessity.  Drawing upon some suggestive gestures toward agency input in 





  Riegel, 128 S. Ct. at 1009.  Here, Justice Stevens jumped off the majority bandwagon, rejecting 
this ―policy argument advanced by the Court, not by Congress.‖  Id. at 1012 (Stevens, J., concurring in 
part and concurring in the judgment). 
17
  Sharkey, Products Liability Preemption, supra note 11, at 452–53, 477–502 (setting forth a func-
tional institutional approach to implied conflicts products liability preemption whereby courts accord 
Skidmore deference to agency preemption determinations, conditioned on strong record evidence con-
cerning regulatory cost benefit analysis and a reasoned determination of the need for a uniform national 
policy). 
18
  128 S. Ct. 1118 (No. 06-1249), cert. granted, 76 U.S.L.W. 3018 (U.S. Jan. 18, 2008) (to be ar-
gued October Term 2008).  The Court will consider ―[w]hether the prescription drug labeling judgments 
imposed on manufacturers by the [FDA] pursuant to FDA‘s comprehensive safety and efficacy authority 
under the [FDCA] preempt state law product liability claims premised on the theory that different labe-
ling judgments were necessary to make drugs reasonably safe for use.‖  Supreme Court of the United 
Strates, Question Presented for Wyeth v. Levine, available at 
http://origin.www.supremecourtus.gov/qp/06-01249qp.pdf (link). 
102:415  (2008) What Riegel Portends for FDA Preemption 
http://www.law.northwestern.edu/lawreview/colloquy/2008/24/ 419 
of the regulation of pharmaceutical drugs and extends the model by specify-
ing searching judicial review of evidence taken from the FDA‘s regulatory 
record (record evidence) to substantiate FDA findings of implied conflicts 
between state common law failure-to-warn claims and the federal regulation 
of the safety and efficacy of drugs. 
I. AGENCY INPUT 
Judicial reliance on input from federal agencies in making preemption 
decisions is not as radical as it might at first seem.  Indeed, although often 
barely acknowledged, reliance on agencies‘ views in regulatory preemption 
cases has been a staple of Supreme Court jurisprudence.19  Riegel fits this 
pattern of cryptic reliance on agency positions.  For, although ultimately 
decided as an express preemption case based on unambiguous statutory 
text, Riegel nonetheless gives a nod toward agency deference, suggesting 
that, had the statute been ambiguous, the Court would have taken into ac-
count the FDA‘s position on preemption. 
Riegel provided the Court a second opportunity to interpret the 
preemption provision of the Medical Devices Amendments to the FDCA.  
The earlier case, Medtronic v. Lohr,20 likewise an express preemption case, 
thus presents a foil to Riegel.  To begin, the Court reached the opposite bot-
tom line conclusion on preemption in Lohr, so the differences between the 
two cases can be probed for salient preemption factors.  More fundamental-
ly, Lohr‘s acknowledgement of ―[t]he ambiguity in the statute,‖ and con-
comitant reliance upon ―the agency‘s view of the statute,‖21 places Riegel‘s 
paeon to statutory text in sharp relief. 
Given its finding of statutory ambiguity in the MDA, Lohr ventured 
part way down the implied preemption path, acknowledging that the FDA 
―is uniquely qualified to determine whether a particular form of state law 
‗stands as an obstacle to the accomplishment and execution of the full pur-
poses and objectives of Congress.‘‖22  Considering Lohr and Riegel together 
provides not only an opportunity to examine how the Court has previously 
taken into account agency input in a medical device preemption case, but 
also an occasion to provide guidance on how the Court should use agency 
input, not only in express preemption cases, but perhaps even more signifi-
cantly, in implied preemption cases, such as the upcoming Wyeth pharma-
ceutical case. 
Section A focuses on the agency‘s preemption position, expressed in 
the form of enacted regulations or other more informal statements, ultimate-





  See Sharkey, Products Liability Preemption, supra note 11, at 471–72. 
20
  518 U.S. 470 (1996) (link). 
21
  Id. at 496 (―The ambiguity in the statute . . . provide[s] a sound basis for giving substantial weight 
to the agency‘s view of the statute.‖) (citations omitted) (quoting id. at 509 (O‘Connor, J., dissenting)). 
22
  Id. (quoting Hines v. Davidowitz, 312 U.S. 52, 67 (1941)). 
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should be instead on how regulations are actually administered by the agen-
cy.  Section B turns to this administration, proposing that, when trying to 
determine whether or not state law should be preempted by federal agency 
action, courts should look to the regulatory record to determine whether or 
not an agency actually considered the risks that the state law attempts to 
protect against. 
A. Preemption Position 
Agencies have a variety of means at their disposal to express their po-
sition on preemption, from notice-and-comment rulemaking to less formal 
interpretive statements, preambles to rules, and litigation briefs.23 
1.  Regulations.—The Lohr majority‘s interpretation of the MDA‘s ex-
press preemption provision was ―substantially informed‖ by an FDA regu-
lation.24  The FDA had issued a regulation construing the scope of the 
preemption provision, which sharply cabined its preemptive force.25  The 
FDA took the further position that the MDA ―does not preempt State or lo-
cal requirements of general applicability where the purpose of the require-
ment relates . . . to other products in addition to devices.‖26  The Lohr Court 
relied on these interpretations in finding that the FDA‘s premarket notifica-
tion process did not amount to device-specific preemptive requirements.27 
In contrast, the majority in Riegel toed the textualist statutory interpre-
tation line, concluding that ―the [same FDA] regulation fails to alter our in-
terpretation of the [statutory] text insofar as the outcome of this case is 
concerned.‖28  But, ―[e]ven assuming that this regulation could play a role in 
defining the MDA‘s pre-emptive scope,‖ and recognizing that ―[t]he agen-
cy‘s reading of its own rule is entitled to substantial deference,‖29 the Court 
nonetheless dispensed with the FDA‘s interpretation of its regulation, find-
ing its reasoning ―less than compelling.‖30 
The most striking feature here is the Riegel majority‘s equivocation 





  For a discussion of the recent trend of agencies‘ issuance of ―preemption preambles‖ to regula-
tions, see Catherine M. Sharkey, Preemption by Preamble: Federal Agencies and the Federalization of 
Tort Law, 56 DEPAUL L. REV. 227 (2007) [hereinafter Sharkey, Preemption by Preamble]. 
24
  Lohr, 518 U.S. at 495. 
25
  Exemptions from Federal Preemption of State and Local Medical Device Requirements, 21 
C.F.R. § 808.1(d) (2007) (restricting preemption to instances where FDA had established ―specific 
counterpart regulations or . . . other specific requirements applicable to a particular device‖). 
26
  Id. § 808.1(d)(1) (listing, as examples, general electrical codes, the Uniform Commercial Code‘s 
warranty of fitness and unfair trade practices). 
27
  See Lohr, 518 U.S. at 501. 
28
  Riegel v. Medtronic, Inc., 128 S. Ct. 999, 1011 (2008) (―All in all, we think that [the FDA regula-
tion] can add nothing to our analysis but confusion.‖) (link). 
29
  Id. at 1010 (citing Auer v. Robbins, 519 U.S. 452, 461 (1997)). 
30
  Id.  In the end, the Court hedges by ―neither accepting nor rejecting the FDA‘s‖ position in light 
of the Court‘s exclusive reliance upon statutory text.  Id. at 1011. 
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interpretive gloss.  The Court ―[n]either accept[s] nor reject[s] the proposi-
tion that this regulation can be properly consulted to determine the statute‘s 
meaning.‖31  Most likely, the equivocation was necessary to carry an eight-
Justice majority and masks a sharper division among the Justices on the is-
sue, likely to rear its head once statutory text can no longer provide cover.32 
2. Informal Statements.—Agencies also state their positions on 
preemption through amicus briefs, preambles to regulations, and other in-
formal statements.  In Riegel, although the majority does not cite the FDA‘s 
amicus brief directly, it does make note of the brief by acknowledging the 
FDA‘s support of the majority‘s pro-preemption position.33 
Court reliance upon agency amicus briefs and preambles to rules 
presents a challenge to notions of appropriate administrative deference.  
While briefs and preambles arguably lack ―the force of law‖ necessary to 
warrant Chevron mandatory deference,34 the doctrine on deference to agen-
cy preambles and amicus briefs—particularly in the realm of preemption—
is far from clear.  Justice Breyer has staked out the position that not only 
should an agency‘s position on preemption be given deference in the face of 
an ambiguous congressional command, but also that the agency can com-
municate that position informally ―through statements in ‗regulations, 
preambles, interpretive statements, and responses to comments.‘‖35 
Justice Breyer‘s strong-form deference to agencies is guided by his 
conviction that agencies have a ―special understanding of the likely impact 
of both state and federal requirements, as well as an understanding of 
whether . . . state requirements may interfere with federal objectives.‖36  The 





  Id. 
32
  Past decisions shed some light here.  Justices Scalia and Thomas (as well as then-Chief Justice 
Rehnquist) joined Justice O‘Connor‘s withering critique of the Lohr majority‘s reliance upon FDA regu-
lations to ―inform‖ its statutory interpretation. Lohr, 518 U.S. at 512 (O‘Connor, J., concurring in part 
and dissenting in part) (―It is not certain that an agency regulation determining the pre-emptive effect of 
any federal statute is entitled to deference . . . .‖).  Wachovia Bank, N.A. v. Watters, 127 S. Ct. 1559 
(2007), is also instructive.  In that case, the majority held that state laws were preempted by the National 
Banking Act, thereby dodging the issue (on which the Court had granted certiorari) whether the interpre-
tation of the Comptroller of the Currency was entitled to Chevron deference.  Id. at 1572.  Chief Justice 
Roberts and Justice Scalia joined Justice Stevens‘s vigorous dissent arguing that, despite the majority‘s 
protestations to the contrary, ―this is a case about an administrative agency‘s power to preempt state 
laws‖ and ―[n]o case from this Court has ever applied such a deferential standard to an agency decision 
that could so easily disrupt the federal-state balance.‖  Id. at 1584–85 (Stevens, J., dissenting). 
33
  See Riegel, 128 S. Ct. at 1009 (―In the case before us, the FDA has supported the position taken 
by our opinion with regard to the meaning of the statute.‖). 
34
  See Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc., 467 U.S. 837 (1984) (link); 
United States v. Mead Corp., 533 U.S. 218, 228 (2001) (link); see also Thomas W. Merrill, The Mead 
Doctrine: Rules and Standards, Meta-Rules and Meta-Standards, 54 ADMIN. L. REV. 807 (2002) (seek-
ing a model through which courts may decide whether an agency action carries the ―force of law‖) 
(link). 
35
  Lohr, 518 U.S. at 505–06 (Breyer, J., concurring). 
36
  Id. at 506 (Breyer, J., concurring). 
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―wholesale‖ observation to scrutiny at the ―retail‖ level of agency regulato-
ry action.  The record evidence developed by the agency, to which I turn 
next, should be critical in courts‘ preemption decisions. 
B. Regulatory Record 
Particularly when called upon to answer whether state law frustrates, or 
stands as an obstacle to, the federal regulatory framework, instead of rely-
ing on agency interpretation or general position on preemption—which not 
only might fall outside the expertise of agencies, but can also be influenced 
by inappropriate political considerations—courts should focus on the regu-
latory record of the agency.37 
Riegel is rife with details from the FDA‘s regulatory review process—
though their precise legal effect, given the Court‘s insistence on governing 
statutory text, is rather opaque.  The Court drills down to the details of the 
FDA‘s review process, repeatedly stressing the ―rigorous‖ nature of its 
premarket approval (PMA) process for medical devices.38  This PMA 
process demands considerable resources and manpower hours, culminating 
in the FDA‘s determination of ―reasonable assurance‖ of the medical de-
vice‘s ―safety and effectiveness.‖39 
The contrast between FDA‘s PMA process (at issue in Riegel) and its 
premarket notification process (at issue in Lohr) is twofold.  Premarket no-
tification is a streamlined process, which is completed in an average of 20 
hours (as compared to the PMA‘s 1,200-hour average).40  So, measured by 
average manpower hours, this type of regulatory review is sixty times more 
lax.  Even more germane is the distinction the Court draws between the 
FDA‘s premarket notification ―equivalence‖ review, which essentially 





  In this respect, I agree, at least in part, with both Richard Epstein‘s and Richard Nagareda‘s tren-
chant analyses of FDA tort preemption to the extent that each has urged an approach centered upon the 
agency‘s regulatory action.  See, e.g., Richard A. Epstein, Why the FDA Must Preempt Tort Litigation: 
A Critique of Chevron Deference and a Response to Richard Nagareda, 1 J. TORT. L. art. 5, at 20, avail-
able at  http://www.bepress.com/jtl/vol1/iss1/art5/ (2006) (―Did the agency make a considered examina-
tion of the various risks when it decided on its course of action?‖) (link); Richard Nagareda, FDA 
Preemption: When Tort Law Meets the Administrative State, 1 J. TORT L. art.4, at 5, available at 
http://www.bepress.com/jtl/vol1/iss1/art4/ (2006) (advocating an approach ―seeking to marry a proper 
understanding of preemption with appropriate design of the underlying regulatory regime‖) (link). 
But, as usual, the devil resides in the details—namely what constitutes an agency‘s ―considered ex-
amination‖ of the precise risks at issue and what level of judicial review—of agency interpretations, ac-
tions, and inaction—should pertain?  Here is where, I think, I push the ball several lengths forward. 
38
  Riegel, 128 S. Ct. at 1003–04. 
39
  Id. at 1004. 
40
  Lohr, 518 U.S. at 478–79. 
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the time of the MDA‘s enactment,41 versus the full-blown PMA ―safety‖ re-
view.42 
In the Riegel Court‘s view, the details of the FDA‘s stringent safety re-
view are relevant to the Court‘s interpretation of the MDA.  The Court em-
phasizes that premarket approval is a safety review, and as such imposes 
―requirements‖ under the MDA.43  But the significance of the FDA‘s level 
of regulatory scrutiny of medical devices to the regulatory preemption in-
quiry is even more far reaching and could prove influential, if not disposi-
tive, in resolving implied conflict preemption disputes, where courts must 
look beyond the statutory text to decide whether or not state common law 
actions obfuscate or impede federal regulatory directives and goals. 
While the Riegel opinion does not pursue this line of inquiry, several of 
the Justices tipped their respective hats in this direction during oral argu-
ment.  Justice Kennedy proffered a concise statement of implied conflict: 
―The FDA is specifically charged [in the PMA process] with weighing the 
[potential] risks [of injury and illness] against the probable benefits [to the 
health of the patient]. . . . So the jury is doing the same thing that the FDA 
did.‖44  Justice Scalia seemed to be of like mind, forging a distinction be-
tween Lohr and Riegel on the basis of whether the jury was engaged in the 
same regulatory function as the FDA: ―[T]he point is that the FDA in Lohr 
had never made a determination of weighing the risks against the benefits, 
as they do for the issuance of PMA‘s.  And so the jury was not replowing 
the same ground that the FDA had already plowed in Lohr.‖45 
The Justices‘ queries here point in exactly the right direction—namely, 
when it comes to making an implied conflict preemption determination, it is 
critical to discern whether the FDA has weighed in on the precise risk the 
state tort action likewise seeks to regulate.  Such a framework will focus 
judicial attention on the regulatory record compiled by the agency, contem-
poraneously with its decision whether or not to take regulatory action. 
II. JUDICIAL REVIEW 
The Riegel majority had little to say about judicial review of agency 





  Id. at 480 (noting that the FDA‘s ―substantial equivalence‖ letter to the manufacturer ―empha-
sized . . . that this determination should not be construed as an endorsement of the pacemaker lead‘s 
safety‖). 
42
  Riegel, 128 S. Ct. at 1004 (describing the safety review process that calls upon the FDA to 
―weig[h] any probable benefit to health from the use of the device against any probable risk of injury or 
illness from such use‖) (alteration in original) (internal quotation marks omitted). 
43
  Id. at 1007.  There is a logic to this progression of reasoning, namely: ―the FDA requires a device 
that has received premarket approval to be made with almost no deviations from the specifications in its 
approval application, for the reason that the FDA has determined that the approved form provides a rea-
sonable assurance of safety and effectiveness.‖  Id. 
44
  Riegel Oral Argument, supra note 15, at 6–7. 
45
  Id. at 8.  Justice Alito, too, asked questions in this same vein.  Id. at 30–32. 
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text to the question at hand.  But what little the Court did have to say may 
have resolved (at least in dicta) a simmering debate over the appropriate 
level of deference due to agency views on preemption: 
In the case before us, the FDA has supported the position taken by our opinion 
with regard to the meaning of the statute.  We have found it unnecessary to re-
ly upon that agency view because we think the statute itself speaks clearly to 
the point at issue.  If, however, we had found the statute ambiguous and had 
accorded the agency‘s current position deference, the dissent is correct that—
inasmuch as mere Skidmore deference would seemingly be at issue—the de-
gree of deference might be reduced by the fact that the agency‘s earlier posi-
tion was different.46 
Wrapped up in this quixotic counterfactual musing are two salient doc-
trinal points: first, that ―mere Skidmore‖ deference—which is meted out ac-
cording to the agency‘s ―power to persuade‖ the court, as opposed to 
unconditionally47—is the appropriate level of judicial deference; and 
second, that agency inconsistency is a salient factor, weighing against an 
agency‘s new-found (and by hypothesis, turn-about) position.  What is 
missing is a framework for the Court to undertake judicial review, probing 
the adequacy of the reasons given by the agency for taking a particular ac-
tion, as well as for changing tack and taking a different course of action. 
A. Applying Skidmore Deference 
Skidmore deference trains the court‘s review of an agency‘s interpreta-
tion on ―all those factors which give it power to persuade, if lacking power 
to control,‖ such as ―the thoroughness evident in its consideration, the va-
lidity of its reasoning, [and] its consistency with earlier and later pro-
nouncements.‖48  Perhaps the sole point of agreement between the majority 
and dissent in Riegel was that if Skidmore deference were to apply, then the 
court should consider whether the FDA‘s position on preemption merited 
less deference on account of its inconstancy. 
Twelve years before Riegel, under the Clinton administration, the FDA 
publicly endorsed an anti-preemption position vis-à-vis the MDA‘s regula-
tion of medical devices.  Before the Court in Lohr, the FDA put forward a 





  Riegel, 128 S. Ct. at 1009 (citation omitted); see also id. at 1015-16 & n.18 (noting that the FDA 
had reversed its ―long  held view‖ against preemption and that the ―FDA‘s new position is entitled to 
little weight‖) (Ginsburg, J., dissenting). 
47
  Skidmore v. Swift & Co., 323 U.S. 134, 140 (1944) (link). 
48
  Id.  See Kristen E. Hickman & Matthew D. Kreuger, In Search of the Modern Skidmore Stan-
dard, 107 COLUM. L. REV. 1235, 1281–91 (2007) (demonstrating, based upon a review of more than one 
hundred recent federal appellate cases applying Skidmore deference, that courts tend to apply Skidmore 
as a sliding scale based upon five key factors: (1) the thoroughness of the agency‘s consideration, (2) the 
formality of the agency‘s procedure in staking out its interpretation, (3) the validity of the agency‘s rea-
soning, (4) the consistency of the agency‘s interpretations, and (5) the relevance of agency expertise) 
(link). 
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mate responsibility for its design of medical devices.49  And the year follow-
ing Lohr, in an amicus brief urging the Court to grant certiorari in another 
medical devices case (where the catheter device at issue had gone through 
the full PMA process), the FDA took the position that the MDA‘s preemp-
tion provision is not preemptive.50 
Fast forward to the Bush II administration.  The FDA did a seeming 
180-degree turn-about and first articulated its new pro-preemption position 
for PMA devices in 2004 in an amicus brief in Horn v. Thoratec,51 a case 
before the Third Circuit Court of Appeals.  The FDA argued that the PMA 
process creates specific federal requirements because, following approval, 
the manufacturer cannot alter the design or labeling of the device without 
FDA approval.52 
Sweeping Chevron deference to agencies on preemption questions 
raises the troubling specter of enabling or encouraging cycles of agency po-
litical flip-flop,53 and, more generally, of foregoing a key judicial check by 
relieving the agency of responsibility to supply an adequate record to subs-
tantiate its position regarding the preemptive effect of federal statutes and 
regulations.  Riegel could in fact be hypothetical ―exhibit A.‖  The FDA‘s 
change in position did not escape notice in Riegel.  Justice Stevens drew at-
tention to it during oral argument.54  And Justice Ginsburg hammered the 
point home that the FDA‘s previous position ―was 180 degrees different.‖55  
Stipulation of the weaker Skidmore deference standard still leaves much to 
be decided.  Namely, how should a court determine whether the agency‘s 
change in position has been reasonably explained? 
B. Demanding Reasonable Explanations 
In the Riegel opinion below, the Second Circuit was little troubled by 
the FDA‘s change of heart; the court explained: ―It is certainly true that the 
FDA previously took a different view, but as the Third Circuit noted in 





  Brief for the United States as Amicus Curiae Supporting Respondents/Cross Petitioners at 20, 
Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996) (Nos. 95-754, 95-886), 1996 WL 118035, at *20. 
50
  Brief for the United States as Amicus Curiae at 13, Smith Indus. Med. Sys., Inc. v. Kernats, 522 
U.S. 1044 (1997) (No. 96-1405), 1997 WL 33561767, at *13. 
51
  376 F.3d 163 (3d Cir. 2004). 
52
  Letter-Brief for the United States as Amicus Curiae at 16–17, Horn v. Thoratec, 376 F.3d 163 (3d 
Cir. 2004) (No. 02-4597), 2004 WL 1143720, at *16–17 [hereinafter Horn Letter-Brief for the United 
States as Amicus Curiae]. 
53
  See, e.g., Epstein, supra note 37, at 15 (―[A]ny court wedded to Chevron deference has to abide 
by [agency decisions regarding preemption] . . . . so that the preemption question could oscillate to and 
fro with a change in personnel and administrations.‖). 
54
  Riegel Oral Argument, supra note 15, at 39. 
55
  Id. at 45; see also Riegel v. Medtronic, Inc., 128 S. Ct. 999, 1015–16 & n.8 (2008) (Ginsburg, J., 
dissenting) (link). 
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with ―reasoned analysis,‖‘ a standard satisfied here.‖56  But the FDA pro-
vided little more than an ipse dixit justification of its change in position in 
Horn, based upon its ―further analysis of the relevant legal and policy is-
sues‖ as well as recent contrary court decisions.57 
In its amicus brief filed at the petition stage at the Supreme Court, the 
Solicitor General added only that ―[t]he government‘s [previous anti-
preemption] position . . . is also inconsistent with the risk-management 
principles that the FDA currently follows.‖58  The government seemed to re-
ly heavily on the notion that its position is entitled to substantial deference 
and that its explanation of ―risk-management principles‖ and ―the need to 
prevent over-warning‖ should suffice to demonstrate the incompatibility of 
state tort law with the FDA regulatory standards.   
The government‘s proffers based solely on its ―judgment‖ or new poli-
cy preferences—of the sorts offered in Horn and Riegel—should not pass 
judicial muster in implied conflict preemption cases.  Instead, courts should 
apply searching review and require direct, hard evidence from the agency‘s 
regulatory record of how state common law conflicts with the federal regu-
latory scheme and, where applicable, the basis for any change in agency po-
sition.59  Justice Alito made a gesture in this direction, when he asked 
during the Riegel oral argument whether the PMA regulatory record would 





  Riegel v. Medtronic, Inc., 451 F.3d 104, 125 (2d Cir. 2006) (citing Motor Vehicle Mfrs. Ass‘n v. 
State Farm Mut. Auto. Ins. Co., 463 U.S. 29, 42 (1983)). 
57
  Horn Letter-Brief for the United States as Amicus Curiae, supra note 52, at 3. 
58
  Brief for the United States as Amicus Curiae, On Petition for Writ of Certiorari, at 17, Riegel v. 
Medtronic, 128 S. Ct. 999 (2008) (No. 06-179), 2007 WL 1511526.  The SG expanded upon this ratio-
nale only a tad in its amicus brief at the merits stage: ―[T]he United States‘ earlier position was based in 
part on proposed regulations that FDA has since withdrawn, and its prior position is inconsistent with 
FDA‘s current understanding and application of the risk-management principles discussed above (e.g., 
the need to prevent over-warning).  Neither FDA‘s reasoned change in position, nor the absence of a 
formal agency regulation addressing the specific question presented here, negates deference.‖  Brief for 
the United States as Amicus Curiae Supporting Respondent at 24, Riegel v. Medtronic, Inc., 128 S. Ct. 
999 (2008) 2007 WL 3231418, at *24 [hereinafter Riegel Brief for the United States as Amicus Curiae] 
(citing Auer v. Robbins, 519 U.S. 452, 461–62 (1997)). 
59
  Brian Galle and Mark Seidenfeld have likewise called for something akin to Skidmore deference, 
coupled with a type of ―hard look‖ review, which would allow agencies the flexibility to change their 
position when necessary, offering agencies incentive to show that they reached their decision through 
―good and open deliberation.‖  Brian D. Galle & Mark Seidenfeld, Administrative Law‟s Federalism: 
Preemption, Delegation, and Agencies at the Edge of Federal Power, 57 DUKE L.J. (forthcoming 2008), 
available at http://ssrn.com/abstract=1101141.  See also Motor Vehicle Mfrs. Ass‘n v. State Farm Mut. 
Auto. Ins. Co., 463 U.S. 29, 42–43 (1983) (―[A]n agency changing its course by rescinding a rule is ob-
ligated to provide a reasoned analysis for the change . . . .  [T]he agency must examine the relevant data 
and articulate a satisfactory explanation for its action.‖).  I have in mind something like ―State Farm 
with teeth,‖ keeping in mind that the Second Circuit gave the green light to the FDA‘s changed position 
pursuant to what I would characterize as a ―lax State Farm‖ standard, see supra notes 56–57 and ac-
companying text. 
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considered by the FDA.60  The informational demands of such an approach 
are significant, which perhaps explains why it has been resisted by the 
FDA.61 
The Riegel Court did not have to squarely face these issues of appro-
priate deference to the FDA, or judicial review of the bases for its preemp-
tion position, given the Court‘s exaltation of statutory text.  The Court, 
moreover, declined to venture down the implied conflict preemption path, 
where it might have taken account of, and accorded Skidmore deference to, 
the FDA‘s preemption position, the basis for which it would then subject to 
some level of judicial scrutiny.  These issues are sure to rear their head in 
future challenges before the Court. 
III. FUTURE CHALLENGES: PHARMACEUTICALS 
In the wake of Riegel, what will the state law products liability land-
scape look like?  Riegel certainly narrows the scope of state law claims of 
allegedly defective FDA-approved medical devices that can withstand a 
federal preemption challenge.  That said, claims of tort litigation‘s demise 
in the arena of medical devices, let alone all of products liability, have been 
overstated.62 
Four caveats to the Court‘s opinion suggest categories of surviving 





  Riegel Oral Argument, supra note 15, at 31–32 (―If you look at the file of a PMA proceeding af-
ter it is concluded, can you tell exactly which design features and which risks the FDA has consi-
dered?‖). 
61
  In response to Justice Alito‘s question, Wyeth‘s attorney answered: ―No, I don‘t think you can . . 
. . The FDA will have examined, and presumably done its job, with respect to every aspect of the design, 
manufacture, and labeling of the device. . . .‖  Id. at 32 (Mr. Olson).  The government likewise resisted 
the suggestion: 
We don‘t think that a preemption test can really realistically turn on that.  That would require ex-
tensive and intrusive inquiry into what FDA had done.  We think that the best way to look at this is 
what the end product was . . . .  You look at what was put before the agency and what was ap-
proved, not what might have gone into—into consideration. 
Id. at 50 (Mr. Kneedler). 
62
  In the wake of Riegel, some news media headlines pronounced the death of claims by those in-
jured by medical devices.  See, e.g., Robert Barnes, Supreme Court Shields Medical Device Makers; 
Decision Rules Out State Lawsuits Over Products That Meet FDA‟s Highest Standards, WASH. POST, 
Feb. 21, 2008, at D1, available at http://www.washingtonpost.com/wp-
dyn/content/article/2008/02/20/AR2008022001140.html (―Yesterday‘s decision seemed in step with the 
court‘s recent rulings favoring business and expressing skepticism about the role of civil lawsuits in dis-
ciplining corporations.‖) (link); Janet McConnaughey, A „Get Out of Jail Free Card‟ for Manufacturers; 
If Regulatory Agency OK‟d Product, Jury Can‟t Second Guess, PITTSBURGH POST-GAZETTE, Mar. 31, 
2008, at A4; see also Editorial, No Recourse for the Injured, NY TIMES, Mar. 22, 2008, at 22, available 
at http://www.nytimes.com/2008/02/22/opinion/22fri1.html?_r=1&oref=slogin (reading Riegel to 
―mean[] that any consumer harmed by a fault device . . . will have no chance of fair compensation and 
the manufacturer will have a dangerous sense of impunity‖) (link). 
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ure to warn) claims are allowed to proceed.63  Second, keeping in mind the 
distinction between Riegel, which addressed itself to devices that were ap-
proved via the FDA‘s PMA process, and Lohr, which pertained to devices 
that had secured approval via the FDA‘s ―substantial equivalence‖ premar-
ket notification process, only manufacturers of medical devices that enter 
the market via PMA (at present, roughly ten percent of relevant devices) 
can use the shield of Riegel to stave off state tort claims using a preemption 
defense.  A third important caveat involves negligence per se actions—state 
tort law actions based upon the violation of a federal regulatory standard.  
The Riegel majority is explicit that ―the state duties in such a case ‗parallel,‘ 
rather than add to, federal requirements‖ and are thus not preempted.64  Fi-
nally, there may be an additional opening for situations where new product 
risks come to light after the FDA‘s initial approval.65  What Riegel portends 
for the future may, nonetheless, lie more in the questions left unanswered, 
or at least not fully answered. 
Pharmaceutical litigation involving FDA-approved drugs lies just over 
the Court‘s horizon.  Indeed, when the Court heard argument in Riegel, the 
specter of the upcoming FDA pharmaceutical preemption case, Wyeth v. 
Levine, loomed large in the background.66  During the Riegel oral argument, 
Justice Scalia turned from devices to drugs, asking (seemingly rhetorically): 
―Then the States can issue regulations that go beyond—beyond what the 
FDA says in drug matters?  I would be surprised if that‘s the case.‖67 
When the Court ruled 8-1 in favor of preemption in Riegel, some 
preemption enthusiasts seemed poised to celebrate an FDA preemption 





  See Riegel v. Medtronic, Inc., 128 S. Ct. 999, 1006 (2008).  Not surprisingly, a proliferation of 
such claims is anticipated.  Drug and Device Law Blog, 
http://druganddevicelaw.blogspot.com/search?q=July+17%2C+2008 (July 17, 2008, 12:27 EST) 
(―Watch out for disguised ‗manufacturing‘ claims. . . . We‘ll need to watch carefully for plaintiffs trying 
to pass off what are really Riegel-preempted design defect claims . . . as so-called ‗manufacturing‘ 
claims.‖) (link). 
64
  Riegel, 128 S. Ct. at 1011. 
65
  See id. at 1013 n.1 (Ginsburg, J., dissenting) (―The Court‘s holding does not reach an important 
issue outside the bounds of this case: . . . where evidence of a medical device‘s defect comes to light on-
ly after the device receives premarket approval.‖).  The majority opinion is silent here—although several 
of the Justices took an interest in this issue during oral argument, see Riegel Oral Argument, supra note 
15, at 26–27 (Roberts, C.J.); id. at 27–28 (Kennedy, J.); id. at 28 (Stevens, J.); id. at 29 (Souter, J.)—so 
perhaps the most that can be said is that this is an open (and sure to be heavily litigated) issue.  The ap-
proach I have advocated—with due attention to the agency‘s regulatory record as to the precise risk re-
gulated—is consistent with Justice Ginsburg‘s position here. 
66
  See Riegel, 128 S. Ct. at 1018–19 & n.16 (Ginsburg, J., dissenting). 
67
  Riegel Oral Argument, supra note 15, at 11.  Justice Scalia‘s view of Riegel seemed to go the far-
thest, pushing beyond implied conflict preemption to the broader realm of implied field preemption.  Id. 
at 12 (―It is field preemption, isn‘t it?‖).  This more expansive view was taken up by the government, 
arguing as amicus curiae in support of the respondent device manufacturer.  See id. at 42 (―[M]aybe in 
this context it is best to conceptualize it as field preemption, of the things that are included within the 
application that is submitted to the FDA and the labeling.‖). 
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pharmaceutical preemption cases to come, Kent v. Warner-Lambert,68 a 
fraud-on-the-agency case also decided last Term, and Wyeth.69  The eight-
person majority, after all, rose against Justice Ginsburg‘s lone dissenting 
voice to clarify that ―[i]t has not been established (as the dissent assumes) 
that no tort lawsuits are pre-empted by drug or additive approval under the 
FDCA.‖70  But selective parsing of Court opinions has its perils.  For, far 
from intimating that its decision in Riegel would preordain the same result 
in the pharmaceutical context, the Court emphasized a key statutory distinc-
tion between the realms of medical devices and drugs: a preemption clause 
applies to the former, but not the latter.71  The whole game, then, switches 
from express preemption in Riegel to implied conflict preemption in 
Wyeth.72  Moving the battleground from express preemption (in medical de-
vices context) to implied preemption (in pharmaceutical context) is likely to 
divide the ranks, as was the case in Kent, where the Court handed down its 





  Warner-Lambert Co. v. Kent, 128 S. Ct. 1168 (2008) (per curiam) (link). 
69
  See Posting of Ted Frank to PointofLaw.com, 
http://www.pointoflaw.com/archives/2008/02/riegel-v-medtronic.php (Feb. 20, 2008, 24:38 EST) (call-
ing Riegel ―[a] phenomenally good . . . decision [that] . . . bodes well for the cause of federal preemption 
in the pending [Kent] and [Wyeth] cases‖) (link); Drug and Device Law Blog (Feb. 20, 2008), 
http://druganddevicelaw.blogspot.com/2008/02/more-on-riegel.html (Feb. 20, 2008, 08:13 EST) (―[W]e 
have to say that we feel better about [Wyeth] after reading [Riegel].‖) (link); see also Posting of Amanda 
to Poptort.com (Feb. 21, 2008), http://www.thepoptort.com/2008/02/in-love-us-supr.html (Feb. 21, 
2008, 11:46 EST) (lamenting that Riegel ―was clearly a Valentine gift (a few days belated) to drug com-
panies—and there‘s more to come!‖) (link). 
In a telling exchange during the Kent oral argument, Justice Breyer certainly telegraphed his lean-
ings as well.  See Transcript of Oral Argument at 30, Warner-Lambert Co., 128 S. Ct. 1168 (No. 06-
1498) (―Now, who would you rather have make the decision as to whether this drug is, on balance, 
going to save people or, on balance, going to hurt people?  An expert agency, on the one hand, or 12 
people pulled randomly for a jury role who see before them only the people whom the drug hurt and 
don‘t see those who need the drug to cure them?‖). 
70
  Riegel, 128 S. Ct. at 1009. 
71
  Id. (―[I]f . . . Congress wanted the two regimes [medical devices and drugs] to be alike; Congress 
could have applied the pre-emption clause to the entire FDCA.  It did not do so, but instead wrote a pre-
emption clause that applies only to medical devices.‖). 
72
  Not only are the FDCA drug provisions bereft of any preemption provision, but they also contain 
a qualified savings clause:  ―Nothing in the amendments  . . . shall be construed as invalidating any pro-
vision of State law which would be valid in the absence of such amendments unless there is a direct and 
positive conflict between such amendments and such provision of State law.‖  Drug Amendments of 
1962, § 202, 76 Stat. 780, 793 (1962) (codified as 21 U.S.C. § 321 (2007)) (link); see also Sharkey, 
Products Liability Preemption, supra note 11, at 503–04 (arguing that ―direct and positive conflict‖ lan-
guage embraces implied conflict preemption of both the impossibility and obstacle/frustration of pur-
poses varieties).  
73
  128 S. Ct. 1168 (2008) (mem). This ―non-decision‖ let stand the Second Circuit opinion below, 
which held that common law tort claims were not impliedly preempted in a case applying a statutory 
fraud exception to a drug liability immunity provision. Id.  For a discussion of the wider implications of 
the issues raised in Kent, see Catherine M. Sharkey, The Fraud Caveat to Agency Preemption, 102 NW. 
U. L. REV. 841 (2008) [hereinafter Sharkey, The Fraud Caveat to Agency Preemption]. 
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Certainly with statutory text unable to take up the gauntlet to resolve 
the preemption question, issues that lurked in the background of Riegel 
come decidedly to the fore.  The presumption against preemption may once 
again rear its head (although quiescent in Riegel) and policy preferences 
could reveal themselves in the guise of pronouncements on the compatibili-
ty of ex ante FDA regulation of drugs with ex post juror resolution of state 
tort claims.  But all eyes should be trained on the Court‘s treatment of the 
FDA‘s involvement. 
A. FDA Input 
Recall that Riegel can be distinguished from Lohr on the basis of the 
rigor of the PMA process at issue in the former as compared to the premar-
ket notification process in the latter.  The Riegel dissent carries this line of 
analysis into pharmaceuticals, making the point that ―the process for ap-
proving new drugs is at least as rigorous as the [PMA] process for medical 
devices.‖74  Justice Ginsburg means for this to be a strike against reliance 
upon the rigor of FDA regulatory review, staking her argument on the claim 
that courts have not found that FDA approval of drugs preempts state tort 
lawsuits.  The Riegel majority instead takes the rigor of the device approval 
process to support its pro-preemption interpretation of the MDA. 
As I suggested above, the significance is even greater in the realm of 
implied conflict preemption analysis, where the question whether allowance 
of state tort law claims enables a jury to ―redo‖ the very same cost-benefit 
analysis conducted by the agency is relevant to a court‘s consideration of 
whether state tort law impedes the federal regulatory process.  With this in 
mind, the details of the FDA drug approval process provided by Justice 
Ginsburg take on an added significance.75  As summed up by the Solicitor 
General in Riegel, ―FDA‘s risk-benefit balancing for devices is parallel to 
the risk-benefit balancing it undertakes . . . as part of the pre-market ap-





  Riegel, 128 S. Ct. at 1018 (Ginsburg, J., dissenting); see also Riegel Oral Argument, supra note 
15, at 25 (Ginsburg, J.) (―I would think that if everything that [counsel for device manufacturer] said 
about new devices would apply in bold letters to new drugs, because the testing procedures are much 
longer, are they not?‖). 
75
  See Riegel, 128 S. Ct. at 1018–19 n.15 (Ginsburg, J., dissenting) (citations omitted) (recounting 
the details of the FDA‘s process for approving a new drug). 
76
  Riegel Brief for the United States as Amicus Curiae, supra note 58, at 11; see also Brief of the 
United States as Amicus Curiae Supporting Petitioner at 13–15, Wyeth v. Levine, 128 S. Ct. 1118 
(2008) (No. 06-1249), 2008 WL 2308908, at *13–15 [hereinafter Wyeth Brief of the United States as 
Amicus Curiae Supporting Petitioner] (―FDA‘s ‗rigorous evaluation process‘ . . . scrutinizes everything 
about the drug—from the design of clinical trials to the severity of side effects to the conditions under 
which the drug is manufactured.  [A]n FDA review team—medical doctors, chemists, statisticians, mi-
crobiologists, pharmacologists, and other experts—evaluates whether the studies the sponsor submitted 
show that the drug is safe and effective for its proper use.‘‖) (alterations in original) (quoting FDA, The 
FDA‟s Drug Review Process: Ensuring Drugs Are Safe and Effective (Review Process) (visited June 2, 
2008), http://www.fda.gov/fdac/special/testtubetopatient/drugreview.html). 
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Further questions must be asked, however, in the context of drugs, 
which is governed by implied conflict preemption analysis: Does FDA reg-
ulation (including rigorous approval processes ensuring the safety and effi-
cacy of drugs) constitute a minimal safety ―floor‖ or an optimal level of 
protection, and thus a regulatory ―ceiling‖ as well?  Even if the latter, which 
precise risks (costs) has the FDA considered and weighed in on in the 
course of its risk-benefit balancing?  Only then can we know whether al-
lowing state tort claims to proceed when FDA-approved drugs cause harm 
will obstruct the federal regulatory process. 
Chief Judge Reiber, the dissenting judge in the Wyeth lower court opi-
nion, perceived such a conflict.  To him, the issue was fairly clear-cut: 
―FDA concluded that the drug—with its approved methods of administra-
tion and as labeled—was both safe and effective,‖ whereas the ―jury con-
cluded that the same drug—with its approved methods of administration 
and as labeled—was ‗unreasonably dangerous.‘‖77  But the Wyeth majority 
embraced the view that the FDA standards were minimal ones, rife for en-
hancement by state tort law. The majority‘s interpretation is buttressed by 
the literal language of an FDA regulation, known as the ―changes being ef-
fected‖ (CBE) regulation, that seems to permit drug manufacturers to add or 
strengthen FDA-approved warnings, at least in certain circumstances.78  In 
1979, moreover, the FDA said that its regulations did not prohibit labeling 
changes made to add or strengthen warnings without prior FDA approval.79 
Today, the FDA takes the interpretive position that the CBE should be 
read to apply only to ―newly discovered risks‖—although those words do 
not appear in the regulation.80  The FDA relies upon its policy not to take 
enforcement action against a manufacturer that modifies a label absent FDA 
approval in light of newly discovered risk information.81  Recently, the FDA 
has proposed a rule to codify what it says is the ―agency‘s longstanding 





  Levine v. Wyeth, 944 A.2d 179, 197 (Vt. 2006) (Reiber, C.J., dissenting). 
78
  The CBE regulation permits a drug manufacturer which has filed a supplemental new drug appli-
cation to the FDA to implement a labeling change before the FDA has acted on the application either 
―[t]o add or strengthen a contraindication, warning, precaution, or adverse reaction‖ or ―[t]o add or 
strengthen an instruction about dosage and administration that is intended to increase the safe use of the 
drug product.‖  21 C.F.R. § 314.70(c)(6)(iii)(A),(C) (2007). 
79
  Labeling and Prescription Drug Advertising, 44 Fed. Reg. 37,434, 37,447 (June 26, 1979). 
80
  Brief for Petitioner at 10, Wyeth v. Levine, 128 S. Ct. 1118 (2008) (No. 06-1249), 2008 WL 
2273067 [hereinafter Wyeth Brief for Petitioner].  According to Wyeth, ―[t]hat reading is supported by 
the history of the regulation and its relationship to the purposes of the FDCA as a whole; it is also the 
interpretation that FDA has reasonably advanced.‖  Id. at 27. 
81
  In addition, ―as a practical matter, FDA encourages sponsors to consult with FDA prior to adding 
safety-related information to the labeling for an approved product even when such a change is submitted 
in a CBE supplement, and sponsors typically do so.‖  Supplemental Applications Proposing Labeling 
Changes for Approved Drugs, Biologics, and Medical Devices, 73 Fed. Reg. 2848, 2849 (proposed Jan. 
16, 2008) (to be codified at 21 C.F.R. pts. 314, 601, 814). 
82
  Id. at 2849. 
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low manufacturers unilaterally to add new warnings to drugs would ―un-
dermine the FDA approval process required by Congress.‖83  The FDA thus 
wants to circumscribe the domain of unilateral manufacturer labeling activi-
ty to what it defines as ―newly discovered risks.‖84  The Solicitor General 
has pressed this view before the Supreme Court in Wyeth.85 
The FDA‘s new proposed rule is of a piece with its earlier 2006 
―preemption preamble‖ to a rule on the content and format of drug labels, 
which sets forth the FDA‘s belief that ―FDA approval of labeling under the 
act . . . preempts conflicting or contrary State law.‖86  In the preamble, the 
FDA asserts that ―product liability lawsuits have directly threatened the 
agency‘s ability to regulate manufacturer dissemination of risk information 
for prescription drugs in accordance with the [FDCA].‖87  In both the earlier 
preemption preamble and the recent proposed CBE regulation, the agency 
squarely takes the position that the new drug approval process, culminating 
in the FDA‘s finding that a drug is ―safe and effective‖ under the conditions 
as stated in its labeling constitutes optimal, or ceiling, safety standards, as 
opposed to minimal, or floor, ones.  According to the FDA, ―[t]he center-
piece of risk management for prescription drugs generally is the labeling 
which reflects thorough FDA review of the pertinent scientific evidence.‖88 
B. Judicial Review 
The potential clash between federal regulation and state tort law is 
premised upon the FDA‘s claim—as put forward in its preemption pream-
ble, the proposed CBE regulation, and in the Solicitor General‘s amicus 
brief in Wyeth—that the agency is engaged in setting optimal, as opposed to 
minimal, standards.  As I have emphasized, input from the relevant agency 
on the question of interference with federal regulatory schemes is critical 
for courts to make implied conflict preemption decisions.  But, equally im-






  Id. (explaining that unilateral decisions by the manufacturer ―would disrupt FDA‘s careful ba-
lancing of how the risks and benefits of the product should be communicated‖). 
84
  Id. at 2850 (defining ―newly acquired information‖ on safety as ―data, analyses, or other informa-
tion not previously submitted to the agency, or submitted within a reasonable time period prior to the 
CBE supplement, that provides novel information about the product, such as a risk that is different in 
type or severity than previously known risks about the product‖). 
85
  See Wyeth Brief of the United States as Amicus Curiae Supporting Petitioner, supra note 76, at 
22 (arguing that a manufacturer can unilaterally change a drug label only ―to correct concerns about 
newly discovered risks from use of the drug‖) (quoting 47 Fed. Reg. 46,622, 46,623 (Oct. 19, 1982)) 
(emphasis added in original)); see also id. at 15 (noting that manufacturers typically consult with the 
FDA before making any changes to the drug‘s labeling). 
86
  Requirements on Content and Format of Labeling for Human Prescription Drug and Biological 
Products, 71 Fed. Reg. 3922, 3934 (Jan. 24, 2006). 
87
  Id. 
88
  Id. 
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The FDA‘s main concern with allowing state tort claims on top of 
FDA regulation of drug labels is the risk that overwarning can harm pa-
tients and interfere with regulatory goals.89  In its preemption preamble, the 
FDA claimed that ―additional requirements for the disclosure of risk infor-
mation are not necessarily more protective of patients‖ and cautioned that 
an overabundance of warnings ―can erode and disrupt the careful and truth-
ful representation of benefits and risks that prescribers need to make appro-
priate judgments about drug use.‖90  The nefarious effects of overwarning 
induced by state tort liability are (at least) two-fold.  First, there is the risk 
of warning dilution, namely, ―labeling that includes theoretical hazards not 
well-grounded in scientific evidence can cause meaningful risk information 
to lose its significance.‖91  Second, ―[e]xaggeration of risk, or inclusion of 
speculative or hypothetical risks, could discourage appropriate use of a 
beneficial drug.‖92  In sum, according to the FDA, ―where warnings are 
concerned, more is not always better.‖93 
The FDA preemption preamble suffers from serious procedural irregu-
larities, including the fact that in the original notice of proposed rulemak-
ing, the FDA stated that its proposed rule would not preempt state tort law; 
only at the end of the process, after the comment period had closed, did the 
FDA switch its position and insert the contrary position into the preamble 
of the final rule.94  The process failure bespeaks lack of engaged debate on 
the matter and certainly raises the bar with respect to the kind of evidence 
the FDA would have to provide to substantiate preemption.  While the 
preamble seems a fairly egregious process failure, more generally, agencies 
are notorious for flouting the congressional and executive commands that 
they conduct federalism impact statements and carefully assess any alleged 
conflict between their regulations and state tort law.  I have previously sug-
gested that courts should condition deference to agencies‘ regulations on 





  Here, I put to one side the arguably separate and important interest in uniformity.  Brief for the 
United States as Amicus Curiae at 5, In re Paxil Litig., No. CV 01-07937 MRP, 2002 WL 31375497, at 
*5 (C.D. Cal. Sept. 5, 2002) (―[T]he public undoubtedly would receive inconsistent information from 
region to region.‖). 
90
  71 Fed. Reg. at 3935. 
91
  73 Fed. Reg. at 2851 
92
  Id.; see also 71 Fed. Reg. at 3935. 
93
  Brief of the United States as Amicus Curiae in Support of Defendants-Appellees at 16, Colacicco 
v. Apotex Inc., 521 F.3d 253 (3d Cir. 2008) (No. 06-3107), 2006 WL 5691532, at *16. 
94
  Sharkey, Preemption by Preamble, supra note 23, at 254 (noting that the FDA‘s decision to insert 
preemptive language in the preamble ―provoked charges that it had flouted its obligation to consult with 
State and local authorities and circumvented the proper notice-and-comment process‖). 
95
  Id. at 256–57 (―Consistent with Executive Order 13,132, courts might condition deference to 
agency interpretations of the preemptive scope of regulations on compliance with various congressional 
and executive measures designed to increase the public participation of states, the legislature, and out-
side political groups: consultation mandates, ‗federalism impact statements,‘ or even notice-and-
comment periods could be required for all preemption statements.‖). 
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In terms of accountability, it is heartening that the FDA is proceeding 
with revisions to the CBE regulation via public notice-and-comment rule-
making—albeit against the backdrop of the Wyeth litigation—and not repli-
cating the mistakes of the procedurally flawed process that led to 
promulgation of the preemption preamble.96 
But the FDA is still trying to accomplish too much at the wholesale 
level by ―legal interpretation‖ and too little at the retail level by way of 
―regulatory record.‖  Applying the framework I have set out above to the 
Wyeth case, the agency‘s regulatory record should have to supply direct, 
hard evidence on the precise risks considered by the FDA and provide some 
record evidence to substantiate the danger of overwarning. 
Wyeth argues that the FDA did in fact conduct a cost-benefit analysis 
with regard to the precise risk at issue, but provides little in the way of 
record evidence to substantiate this claim.97  The Solicitor General more cir-
cumspectly argues that the FDA was ―fully aware‖ of the precise risk.98  
Some ground exists between the SG‘s position that awareness of the risk 
suffices and the plaintiff-respondent‘s position that nothing short of the 
FDA‘s specific rejection of the warning proposed by plaintiff will do.99  The 
difference between awareness of a risk and conducting a thorough risk-risk 
analysis in approving the drug label without requiring further warnings is 
really a matter of the FDA‘s supplying the requisite record evidence to 
show that it thoroughly considered the issue. 
A key problem in this case, however, is that the Vermont Supreme 
Court gave short shrift to the agency and its actions, so there is an incom-
plete regulatory record before the U.S. Supreme Court.100  And plaintiff‘s 
counsel certainly seemed to have free rein to denigrate the FDA‘s role, ex-





  See 73 Fed. Reg. at 2850 (―FDA invites comments regarding the circumstances when information 
regarding a safety issue associated with a drug . . . should be considered newly acquired and thus appro-
priate to be included in a CBE supplement.‖); see also id. at 2853 (―FDA invites comments from State 
and local officials.‖). 
97
  Wyeth Brief for Petitioner, supra note 80, at 28 (referring to FDA‘s ―determination that, with ap-
propriate warnings and instructions . . . the benefits of IV administration . . . outweigh the well-known 
risk of harm‖). 
98
  Wyeth Brief of the United States as Amicus Curiae Supporting Petitioner, supra note 76, at 4 
(―FDA was thus fully aware of the risk of an inadvertent intra-arterial injection, and the labeling or re-
vised labeling it approved uniformly contained warnings to address that risk.‖). 
99
  Here, I agree with the Solicitor General that ―[t]he agency could not reasonably be expected to 
expressly reject every possible variant of approved labeling as part of its decisional process.‖  Id. at 25. 
100
  I have criticized the Vermont Supreme Court‘s Wyeth decision as an example of the ―presump-
tion against preemption‖ run amok.  Sharkey, Products Liability Preemption, supra note 11, at 507 (―In 
the hands of the [Wyeth] Court, the presumption does most of the necessary work to resolve the case.  It 
is as if the presumption casts a wide protective shadow against implied preemption; regardless of the 
precise risk regulated by the FDA or specific agency actions taken, the FDA is taken to impose mini-
mum safety standards, ripe for supplementation by state tort law.‖). 
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FDA to rely on this drug and make the safe decision.  You will make the 
decision.‖101 
The Vermont Supreme Court did not solicit the views of the FDA (nor 
did the FDA intervene in the case on its own).  The agency record evidence 
before the Court consists of letters between Wyeth and the FDA concerning 
the labeling of the anti-nausea drug Phenergan over a span of nearly fifty 
years.  The letters establish that FDA was made aware of the risk posed by 
inadvertent intra-arterial injection of Phenergan.102  What is missing are the 
FDA‘s reasoned explanations of its action in approving the label, notwith-
standing its understanding of the relevant risks, for example, because they 
are outweighed by greater risks inherent in overwarning.103 
With respect to the danger of overwarning, the FDA continues its prac-
tice (also evident in the preemption preamble) of speaking in broad general-
ities.  The FDA is thus vulnerable to criticisms that it has supplied ―abstract 
concerns and dire predictions‖ as opposed to hard ―evidence of interfe-
rence.‖104  Some of the Wyeth amici have tried to come to the FDA‘s aid by 
supplying concrete examples of overwarning.105  But, of course, this cannot 
fill the void with respect to the FDA‘s particular consideration of the inhe-
rent risks in the case at hand.  Moreover, with its proposed CBE regulation, 
the FDA makes a wholesale pitch for deference based upon its general 
overwarning argument.  In a comment to the proposed rule, Senator Kenne-
dy (along with six colleagues) asked point blank for the FDA to substantiate 
its overwarning claim.  In response to his query asking the FDA to provide 
specific examples where a manufacturer had used the CBE procedure to add 





  Joint Appendix at 211, Wyeth v. Levine, 128 S. Ct. 1118 (2008) (No. 06-1249), 2008 WL 
2309484 [hereinafter Wyeth Joint Appendix]. 
102
  See id. at 266–385 (letters between the FDA and Wyeth). 
103
  My read of the scant agency record is that the evidence implies that FDA was not only aware of, 
but had actively considered, the competing risks.  The Vermont Supreme Court, by contrast, was con-
vinced that ―[t]he FDA could have rejected the new warning for any number of reasons, including clari-
ty or technical accuracy, without implicitly prohibiting a stronger warning.‖  Levine v. Wyeth, 944 A.2d 
179, 189 (Vt. 2006).  Disputed inferences, however, should not lie at the heart of a sound implied con-
flict preemption analysis.  My approach seeks to put the analysis on sounder evidentiary footing. 
104
  Regulatory Preemption: Are Federal Agencies Usurping Congressional and State Authority?: 
Hearing Before the S. Comm. on the Judiciary 110th Cong. (1997) (statement of David C. Vladeck, Pro-
fessor of Law, Georgetown University Law Center), available at 
http://www.law.georgetown.edu/oneillinstitute/documents/vladeck_testimony.pdf (last visited July 2, 
2008) (link). 
105
  Brief of Washington Legal Foundation & American College of Emergency Physicians as Amici 
Curiae in Support of Petitioner at 13–26, Wyeth v. Levine, 128 S. Ct. 1118 (No. 06-1249) (June 3, 
2008), 2008 WL 2355771, at *13–26 (describing recent scientific and medical studies demonstrating 
adverse public health consequences of overwarning); Brief of John E. Calfee et al. at 11, Wyeth, 128 S. 
Ct. 1118 (No. 06-1294) (June 3, 2008), 2008 WL 2322237, at *11 (discussing risks of overwarning and 
―‗clutter‘: the presence of so much information that physicians would find it hard to distinguish impor-
tant information from relatively unimportant information and might not even bother to peruse all the in-
formation‖). 
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mere four examples—three of which were examples where the FDA had in 
fact required a stronger warning, and the remaining one involved a label 
that was approved after the manufacturer submitted some additional data.106 
Perhaps the wisest course for the U.S. Supreme Court, then, would be 
to reverse and remand Wyeth, directing the Vermont Supreme Court to put 
into practice something akin to the ―agency reference model‖ with search-
ing judicial review.  Such a framework would, as an initial matter, require 
the court to solicit input from the FDA and to accord deference to FDA 
findings of implied conflict to the extent that they are supported by substan-
tial evidence in the agency record. 
To be sure, judicial scrutiny of the agency record is potentially burden-
some.107  The Solicitor General raises the specter of intrusive, second-
guessing of the agency‘s decisionmaking via costly litigation.108  But there 
are also corresponding long-term gains, not only in terms of ensuring that 
the agency has actually carefully considered the risks at issue,109 but also in 






  Letter from Stephen R. Mason, Acting Assistant Commissioner for Legislation, FDA to The 
Honorable Edward M. Kennedy, Chairman, Committee on Health, Education, Labor, and Pensions 3 
(Mar. 7, 2008), available at 
http://www.regulations.gov/fdmspublic/component/main?main=DocketDetail&d=FDA-2008-N-0032 
(follow the ―Page 2‖ link at the bottom of the page, then follow the ―FDA-2008-N-0032-0023.4‖) (link). 
107
  See, e.g., Ronald J. Krotoszynski, Jr., “History Belongs to the Winners”: The Bazelon-Leventhal 
Debate and the Continuing Relevance of the Process/Substance Dichotomy in Judicial Review of Agency 
Action, 58 ADMIN. L. REV. 995, 1002 (2006) (discussing various challenges facing ―hard look review‖ 
of the substance of agency decisionmaking). 
108
  Wyeth Brief of the United States as Amicus Curiae Supporting Petitioner, supra note 76 (―With 
the passage of time, however, it would be increasingly difficult to reconstruct the agency‘s decisionmak-
ing process . . . preemption analysis would devolve into an intrusive, and potentially inconclusive, 
second-guessing of the agency‘s decisional process.‖). 
109
  If the agency regulatory record before the Court is incomplete in Wyeth, where there was a fifty-
year history of correspondence between the manufacturer and the FDA over various risks, imagine the 
dearth of record evidence that might emerge in other cases.  Moreover, without a developed agency 
record courts will have great difficulty in determining whether evidence of new risks has come to light 
since FDA approval.  The plaintiff in Wyeth apparently did not make any such allegation.  See Brief for 
Petitioner at 27, Wyeth v. Levine, 128 S. Ct. 1118 (2008) ( No. 06-1249), 2008 WL 2273067, at *27 
(―[R]espondent has never suggested that Wyeth had any new information about the risks of IV adminis-
tration of Phenergan that would have warranted a change without FDA approval.‖) (Amended Com-
plaint); Wyeth Joint Appendix, supra note 101, at 16 (alleging that Wyeth had ―known for more than 25 
years of the grave risks associated with inadvertent arterial injection or extravasation of Phenergan, in-
cluding irreversible gangrene and amputation‖).  But, again, this is likely to be a highly controversial 
issue in future cases down the road and one that should not be left to inferences drawn from partial 
agency records. 
110
  See, e.g., Mark Seidenfeld, Cognitive Loafing, Social Conformity and Judicial Review of Agency 
Rulemaking, 87 CORNELL L. REV. 486, 523–26 (2002) (discussing the beneficial effects that the know-
ledge of impending judicial review of an agency record can have of the quality of agency decisionmak-
ing processes) (link); Mark Seidenfeld, The Psychology of Accountability and Political Review of 
Agency Rules, 51 DUKE L.J. 1059, 1064 (2002) (arguing that ―hard look‖ judicial review encourages an 
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CONCLUSION 
We began the preemption inquiry in Riegel with the text of the statute, 
which is where Justice Scalia‘s majority opinion claims we may also end.  
But in cases where Congress has either not been clear or (quite commonly) 
has sent contradictory signals in the statutory language, courts must go fur-
ther down an implied conflict preemption path.  This is just what the Riegel 
majority did, even while disclaiming the need to look beyond the text.  
Where are courts to turn next?  We made a brief stopover to consider the 
presumption against preemption statutory canon of construction; but we did 
not stay long.  Nowhere in the Riegel majority is this once-esteemed canon 
mentioned; if anything, Riegel signals its potential demise, or at least its 
waning influence over the Justices.  We moved on to consider policy prefe-
rences.  As a positive matter, it is difficult not to characterize some portions 
of the Court‘s opinion—both the embrace of the regulatory role of state tort 
law and, further, the perception of the jury as ill-equipped to handle cost-
benefit decisionmaking—as reflecting policy preferences.  But this raises 
troubling normative implications.  The Justices‘ anxiety here manifests it-
self in the Court‘s repeated efforts to ascribe such policy choices to Con-
gress.  But the evidence mustered—the text of the statute—is in fact rather 
oblique on these points. 
So we come finally to a more comfortable resting place, and consider 
the role of federal agencies in assisting courts with their preemption deci-
sionmaking and the concomitant level of judicial scrutiny over agency find-
ings.  The Justices‘ queries during oral argument in Riegel—with Wyeth 
looming in the distance—point in the direction of a new framework for im-
plied conflict preemption decisions: The key is discerning whether the FDA 
has weighed in on the precise risk that the state tort action likewise seeks to 
regulate.  Questions of implied conflict preemption—whether or not state 
common law actions are irreconcilable with, or would stand as an obstacle 
to, frustrate or impede, the command of federal regulatory directives and 
goals—should turn, first and foremost, upon a particularized understanding 
of the regulatory review and action taken by the relevant agency.  Input 
from the relevant agency constitutes one pillar of the framework; the second 
is searching judicial review of the record evidence amassed by the agency 
in support of any preemptive position. 
To whom much is given, much is required.  Under the proposed agen-
cy reference model, the FDA would be given an enhanced role, partnering 
so to speak with the courts in making preemption determinations; for this 
reason, courts must ensure that the actions and positions taken by the FDA 
merit deference.  Redirecting the preemption inquiry in these directions 
would go a long way towards helping courts make implied conflict preemp-
                                                                                                                           
increased sense of accountability in agencies, leading them to ―take greater care and avoid [decision-
making] biases,‖ and to engage in information seeking behavior). 
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tion decisions in products liability cases, where statutory text provides scant 
guidance. 
 
 
